According to ProterixBio, a developer of disease management solutions, results from a recent clinical study of subjects with chronic obstructive pulmonary disease (COPD) were presented at the recent European Respiratory Society International Congress.
Algorithms based on combinations of protein biomarkers were successfully associated with measures of COPD disease activity such as shortness of breath and exacerbation history, which demonstrated the potential for use in patient care and in therapeutic trial design.
“COPD is a leading cause of death and contributor to healthcare spending worldwide,” commented Dr Michael Miller, president and CEO of ProterixBio. “There is an un-met need for molecular tools to assess a patient's disease state and inform clinical decision-making. Our recent COPD clinical study results represent a major milestone for ProterixBio and position the company to deliver products that can impact clinical care and accelerate therapeutics development.”
“Improved measures of disease activity can enable better patient management through more personalised care,” said Dr Fernando Martinez, chief of the division of pulmonary and critical care medicine at Weill Cornell Medical College. “The current study results show the potential of molecular signatures as part of more comprehensive patient assessments. Ultimately, progress towards this goal will improve outcomes and reduce the burden on our COPD patients.”